2024
An in vivo examination of the relationship between metabotropic glutamate receptor 5 and suicide attempts in people with borderline personality disorder
Davis M, Asch R, Weiss E, Wagner A, Fineberg S, Nabulsi N, Matuskey D, Carson R, Esterlis I. An in vivo examination of the relationship between metabotropic glutamate receptor 5 and suicide attempts in people with borderline personality disorder. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2024 PMID: 39613160, DOI: 10.1016/j.bpsc.2024.11.014.Peer-Reviewed Original ResearchBorderline personality disorderPathophysiology of borderline personality disorderSuicide attemptsPersonality disorderPositron emission tomographyAssociated with history of suicide attemptBorderline personality disorder symptomsBPD pathophysiologyPositron emission tomography outcomes measurementsHistory of suicide attemptsMetabotropic glutamate receptor type 5Metabotropic glutamate receptor 5Glutamate receptor 5Comprehensive clinical assessmentFrontolimbic circuitsMDD groupDepressive disorderEmotion regulationPsychiatric conditionsCognitive functionMGlu5Comparison controlsMDDSuicideAssociated with historyDeficits in prefrontal metabotropic glutamate receptor 5 are associated with functional alterations during emotional processing in bipolar disorder
Asch R, Worhunsky P, Davis M, Holmes S, Cool R, Boster S, Carson R, Blumberg H, Esterlis I. Deficits in prefrontal metabotropic glutamate receptor 5 are associated with functional alterations during emotional processing in bipolar disorder. Journal Of Affective Disorders 2024, 361: 415-424. PMID: 38876317, PMCID: PMC11250898, DOI: 10.1016/j.jad.2024.06.025.Peer-Reviewed Original ResearchMetabotropic glutamate receptor 5Bipolar disorderGlutamate receptor 5Positron emission tomographyFear processingEmotional processingAssociated with greater activationEmotion processing taskAssociated with impulsivityFunctional brain differencesAssociated with functional alterationsParietal brain regionsPathology of BDIncreased cortical activityAssociated with difficultiesDepressive disorderHealthy comparisonReceptor availabilityBrain differencesPre/postcentral gyriAttention difficultiesGreater activationBrain regionsPsychomotor functionTreatment developmentPreliminary Study of White Matter Abnormalities and Associations With the Metabotropic Glutamate Receptor 5 to Distinguish Bipolar and Major Depressive Disorders
Fan S, Asch R, Davis M, DellaGioia N, Cool R, Blumberg H, Esterlis I. Preliminary Study of White Matter Abnormalities and Associations With the Metabotropic Glutamate Receptor 5 to Distinguish Bipolar and Major Depressive Disorders. Chronic Stress 2024, 8: 24705470231225320. PMID: 38250007, PMCID: PMC10798116, DOI: 10.1177/24705470231225320.Peer-Reviewed Original ResearchMetabotropic glutamate receptor 5Bipolar disorderGlutamate receptor 5UF FAUncinate fasciculusFractional anisotropyWhole-brain analysisMultimodal neuroimaging approachDifferentiation of BDDiffusion-weighted MRI scansFrontotemporal dysconnectivityFrontotemporal systemFunctional dysconnectivityDepressive disorderNeurobiological mechanismsMGluR5 levelsWhite matterWhite matter abnormalitiesNeuroimaging approachesWM integrityNeural mechanismsMDDWhole-brainWM abnormalitiesReceptor 5
2023
Suicidal Thoughts and Behaviors in Older U.S. Military Veterans: Results From the National Health and Resilience in Veterans Study
Fischer I, Nichter B, Aunon F, Feldman D, Levy B, Esterlis I, Pietrzak R. Suicidal Thoughts and Behaviors in Older U.S. Military Veterans: Results From the National Health and Resilience in Veterans Study. American Journal Of Geriatric Psychiatry 2023, 31: 844-852. PMID: 37211498, PMCID: PMC10731861, DOI: 10.1016/j.jagp.2023.04.013.Peer-Reviewed Original ResearchConceptsPast-year suicidal ideationUS military veteransSuicidal ideationLifetime suicide plansSuicide planNational HealthMilitary veteransSuicide intentVeterans StudySuicide attemptsSuicidal thoughtsRepresentative prevalence estimatesMajor depressive disorderLifetime suicide attemptsU.S. military veteransOlder military veteransDepressive disorderPrevalence estimatesLifetime historyProtective factorsSuicide riskPhysical healthLifetime suicideVeteransSelf-report measures
2022
Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder
Holmes S, Asch R, Davis M, DellaGioia N, Pashankar N, Gallezot J, Nabulsi N, Matuskey D, Sanacora G, Carson R, Blumberg H, Esterlis I. Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder. Biological Psychiatry 2022, 93: 1099-1107. PMID: 36764853, PMCID: PMC10164841, DOI: 10.1016/j.biopsych.2022.10.018.Peer-Reviewed Original ResearchConceptsMajor depressive disorderMetabotropic glutamate receptor 5Glutamate receptor 5MGluR5 availabilityBipolar disorderPositron emission tomographyHC groupDepressive disorderReceptor 5Emission tomographyHealthy control individualsPossible treatment targetsGlutamate transmissionBD depressionTreatment strategiesBD groupMGluR5Depressive symptomsNovel treatmentsCognitive alterationsTreatment targetsSynaptic plasticityControl individualsAccurate diagnosisSignificant negative correlationImaging synaptic density in depression
Holmes SE, Abdallah C, Esterlis I. Imaging synaptic density in depression. Neuropsychopharmacology 2022, 48: 186-190. PMID: 35768568, PMCID: PMC9700860, DOI: 10.1038/s41386-022-01368-4.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingPositron emission tomographySynaptic restorationSynaptic densityAdministration of ketamineMajor depressive disorderUnderstanding of depressionSynaptic alterationsSynaptic involvementDepressive disorderMonoamine systemsPreclinical workTreatment resistanceEffective treatmentDendritic spinesResonance imagingEmission tomographyHeterogeneous disorderDepressionDisordersMore researchInitial studyGliaKetamineBoutonsImaging the effect of ketamine on synaptic density (SV2A) in the living brain
Holmes SE, Finnema SJ, Naganawa M, DellaGioia N, Holden D, Fowles K, Davis M, Ropchan J, Emory P, Ye Y, Nabulsi N, Matuskey D, Angarita GA, Pietrzak RH, Duman RS, Sanacora G, Krystal JH, Carson RE, Esterlis I. Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Molecular Psychiatry 2022, 27: 2273-2281. PMID: 35165397, PMCID: PMC9133063, DOI: 10.1038/s41380-022-01465-2.Peer-Reviewed Original ResearchConceptsKetamine's therapeutic effectsMajor depressive disorderTherapeutic effectPositron emission tomographyPosttraumatic stress disorderHealthy controlsSynaptic connectionsSynaptic vesicle protein 2APost-synaptic mechanismsEffects of ketamineDiscovery of ketamineNon-human primatesAntidepressant effectsDepressive disorderSingle administrationSynaptic densityPsychiatric disordersDepression severityKetamineEmission tomographyTerminal densityLiving brainStress disorderRobust reductionDissociative symptomsDifferential Role of mGluR5 in Cognitive Processes in Posttraumatic Stress Disorder and Major Depression
Esterlis I, DeBonee S, Cool R, Holmes S, Baldassari SR, Maruff P, Pietrzak RH, Davis MT. Differential Role of mGluR5 in Cognitive Processes in Posttraumatic Stress Disorder and Major Depression. Chronic Stress 2022, 6: 24705470221105804. PMID: 35958037, PMCID: PMC9358555, DOI: 10.1177/24705470221105804.Peer-Reviewed Original ResearchPosttraumatic stress disorderMajor depressive disorderHealthy adultsCognitive functioningFrontolimbic regionsStress disorderCognitive AssessmentCognitive alterationsPoor attentionCognitionMGluR5 availabilityRobust literatureDiagnostic groupsDifferent domainsMetabotropic glutamate receptor type 5Positron emission tomography scanDepressive disorderEmission tomography scanDisordersFunctioningRelationshipSmoking statusTomography scanParticipantsAdults
2021
Macro- and Microscale Stress–Associated Alterations in Brain Structure: Translational Link With Depression
Banasr M, Sanacora G, Esterlis I. Macro- and Microscale Stress–Associated Alterations in Brain Structure: Translational Link With Depression. Biological Psychiatry 2021, 90: 118-127. PMID: 34001371, DOI: 10.1016/j.biopsych.2021.04.004.Peer-Reviewed Original ResearchConceptsMajor depressive disorderStress-related disordersCytoarchitectural alterationsPathophysiology of MDDChronic stress pathologyDepressive-like behaviorChronic stress modelAnimal stress modelsPositron emission tomographyHuman brain tissueAstroglial alterationsSynaptic deficitsNeurochemical changesDepressive disorderBehavioral deficitsRodent modelsBrain tissueEmission tomographyDepression symptomatologyLiving brainBrain structuresNovel drugsTranslational linkStress pathologyDisorders
2020
PET Imaging of Synaptic Vesicle Protein 2A
Finnema S, Li S, Cai Z, Naganawa M, Chen M, Matuskey D, Nabulsi N, Esterlis I, Holmes S, Radhakrishnan R, Toyonaga T, Huang Y, Carson R. PET Imaging of Synaptic Vesicle Protein 2A. 2020, 993-1019. DOI: 10.1007/978-3-030-53176-8_29.ChaptersSynaptic vesicle protein 2APositron emission tomographyAntiepileptic drug levetiracetamInitial PET studiesPET imagingPET studiesSynaptic densityDrug levetiracetamHigh-affinity SV2A ligandsBrain regionsSynaptic density lossNeuropathological diseasesDisease-modifying therapiesLarge patient cohortMajor depressive disorderProtein 2APET imaging resultsPosttraumatic stress disorderPatient groupPatient cohortDepressive disorderClinical valueParkinson's diseaseEfficacy assessmentSynaptic vesicle proteinsKetamine Normalizes the Structural Alterations of Inferior Frontal Gyrus in Depression
Dai D, Lacadie CM, Holmes SE, Cool R, Anticevic A, Averill C, Abdallah C, Esterlis I. Ketamine Normalizes the Structural Alterations of Inferior Frontal Gyrus in Depression. Chronic Stress 2020, 4: 2470547020980681. PMID: 33426409, PMCID: PMC7758564, DOI: 10.1177/2470547020980681.Peer-Reviewed Original ResearchMajor depressive disorderPost-traumatic stress disorderMagnetic resonance imagingAcute ketamine administrationKetamine administrationKetamine infusionMDD subjectsInferior frontal gyrusComorbid post-traumatic stress disorderPTSD groupAcute ketamine treatmentFrontal gyrusHealthy control subjectsIntravenous ketamine infusionRegional volume differencesImpact of ketamineSingle ketamine infusionStructural alterationsFuture therapeutic targetsVoxel-wise t-testsKetamine treatmentControl subjectsDepressive disorderHC groupPTSD subjects
2010
P.1.025 Molecular imaging of beta-2 subunit containing nicotinic acetylcholine receptors in major depressive disorder
Saricicek A, Esterlis I, Ruf B, Maloney K, Muralidharan A, Seibyl J, Tamagnan G, Bois F, Staley J, Bhagwagar Z. P.1.025 Molecular imaging of beta-2 subunit containing nicotinic acetylcholine receptors in major depressive disorder. European Neuropsychopharmacology 2010, 20: s22. DOI: 10.1016/s0924-977x(10)70027-4.Peer-Reviewed Original Research
2008
Nicotinic receptor dysfunction in major depressive disorder: A trait vulnerability marker of depression
Bhagwagar Z, Esterlis I, Ruf B, Muralidharan A, Lorberg B, Saricicek A, Bois F, Tamagnan G, Seibyl J, Staley J. Nicotinic receptor dysfunction in major depressive disorder: A trait vulnerability marker of depression. NeuroImage 2008, 41: t176. DOI: 10.1016/j.neuroimage.2008.04.143.Peer-Reviewed Original Research